4.3 Article

Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression

期刊

ONCOTARGET
卷 6, 期 4, 页码 1900-1919

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2953

关键词

Prostate cancer stem cell; Self-renewal; Castration-resistant prostate cancer; MEK-ERK (MAPK) and STAT3; PTEN and PI3K/AKT

资金

  1. McMaster Institute of Urology
  2. St. Joseph's Hospital

向作者/读者索取更多资源

The cells of the prostate gland are dependent on cell signaling pathways to regulate their growth, maintenance and function. However, perturbations in key signaling pathways, resulting in neoplastic transformation of cells in the prostate epithelium, are likely to generate subtypes of prostate cancer which may subsequently require different treatment regimes. Accumulating evidence supports multiple sources of stem cells in the prostate epithelium with distinct cellular origins for prostate tumorigenesis documented in animal models, while human prostate cancer stem-like cells (PCSCs) are typically enriched by cell culture, surface marker expression and functional activity assays. As future therapies will require a deeper understanding of its cellular origins as well as the pathways that drive PCSC maintenance and tumorigenesis, we review the molecular and functional evidence supporting dysregulation of PI3K/AKT, RAS/MAPK and STAT3 signaling in PCSCs, the development of castration resistance, and as a novel treatment approach for individual men with prostate cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy

Matthew Ramotar, Melvin L. K. Chua, Hong Truong, Ali Hosni, Melania Pintilie, Elai Davicioni, Neil E. Fleshner, Adam P. Dicker, Robert G. Bristow, Hansen H. He, Theo van der Kwast, Robert B. Den, Alejandro Berlin

Summary: The presence of intraductal carcinoma and cribriform architecture, along with the Decipher genomic classifier, have prognostic value in post-prostatectomy radiotherapy for prostate cancer patients. Patients with IDC/CA have a higher risk of relapse, while GC scores can predict biochemical relapse and metastasis rates.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Meeting Abstract Oncology

Comparison of patients with high-risk nonmetastatic clear cell renal carcinoma in adjuvant therapy trials versus nonclinical trial patients.

Jen Hoogenes, Rodney H. Breau, Bimal Bhindi, Ricardo A. Rendon, Simon Tanguay, Antonio Finelli, Alan So, Luke Lavallee, Frederic Pouliot, Jean-Baptiste Lattouf, Lucas W. Dean, Darrel E. Drachenberg, Lori Wood, Naveen S. Basappa, Daniel Yick, Chin Heng, Aaron Richard Hansen, Denis Soulieres, Georg A. Bjarnason, Ranjeeta Mallick, Anil Kapoor

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.

Luke Lavallee, Chris Morash, Fred Saad, Steven Yip, Anil Kapoor, Michael Paul Kolinsky, Frederic Pouliot, Elie Antebi, Darrel Drachenberg, Cristiano Ferrario, Geoffrey Gotto, Robert James Hamilton, Jenny J. Ko, Krista Noonan, Alan So, Shawn Malone, Anousheh Zardan, Kim N. Chi, Sebastien J. Hotte, Tamim Niazi

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

Aly-Khan A. Lalani, Anand Swaminath, Gregory Russell Pond, Scott Carlyle Morgan, Arun Azad, William Chu, Eric Winquist, Anil Kapoor, Michael Bonert, Jonathan L. Bramson, Michael G. Surette, Christina M. Canil, Shankar Siva, Georg A. Bjarnason, Mark Norman Levine, Jim Wright, Sebastien J. Hotte

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).

Matthew Scott Ernst, Vishal Navani, J. Connor Wells, Frede Donskov, Naveen S. Basappa, Chris Labaki, Sumanta K. Pal, Luis A. Meza, Lori Wood, D. Scott Ernst, Bernadett Szabados, Rana R. Mckay, Francis Parnis, Cristina Suarez, Takeshi Yuasa, Anil Kapoor, Ajjai Shivaram Alva, Georg A. Bjarnason, Toni K. Choueiri, Daniel Yick Chin Heng

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).

Austin Kalirai, Isaiah Joy, Sunita Ghosh, Christian K. Kollmannsberger, Aaron Richard Hansen, Myuran Thana, Jeffrey Graham, Daniel Yick Chin Heng, Vincent Castonguay, Georg A. Bjarnason, Rodney H. Breau, Anil Kapoor, Frederic Pouliot, Lori Wood, Naveen S. Basappa

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels

Xiaozeng Lin, Yan Gu, Yingying Su, Ying Dong, Pierre Major, Anil Kapoor, Damu Tang

Summary: This study discovered four novel multigene sets that can accurately predict the relapse and fatality risk of adrenocortical carcinoma (ACC). These sets are associated with critical ACC factors and mesenchymal stem cells, advancing our understanding of ACC and providing potential improvements in ACC management.

CANCERS (2022)

Article Medicine, General & Internal

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

Vishal Navani, Matthew Ernst, J. Connor Wells, Takeshi Yuasa, Kosuke Takemura, Frede Donskov, Naveen S. Basappa, Andrew Schmidt, Sumanta K. Pal, Luis Meza, Lori A. Wood, D. Scott Ernst, Bernadett Szabados, Thomas Powles, Rana R. McKay, Andrew Weickhardt, Cristina Suarez, Anil Kapoor, Jae Lyun Lee, Toni K. Choueiri, Daniel Y. C. Heng

Summary: This study found that treatment with IOVE therapy was associated with a significantly increased likelihood of objective imaging response compared to IOIO therapy. The presence of lung metastases, receipt of cytoreductive nephrectomy, and favorable IMDC risk were associated with an increased likelihood of experiencing objective imaging response.

JAMA NETWORK OPEN (2022)

Article Public, Environmental & Occupational Health

Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States

Cristina Cano Garcia, Nancy Nimer, Mattia Luca Piccinelli, Stefano Tappero, Andrea Panunzio, Francesco Barletta, Reha-Baris Incesu, Zhe Tian, Fred Saad, Anil Kapoor, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Derya Tilki, Alessandro Antonelli, Ottavio De Cobelli, Luis A. Kluth, Andreas Becker, Felix K. H. Chun, Pierre I. Karakiewicz

Summary: The purpose of this study was to compare the five-year overall survival (OS) between clear cell metastatic renal cell carcinoma (ccmRCC) patients and age-and sex-matched population-based controls, with a focus on race/ethnicity. Using the Surveillance, Epidemiology and End Results database, ccmRCC patients of different racial/ethnic backgrounds were identified. The study found that African Americans had the greatest OS difference compared to the controls, followed by Hispanics, Caucasians, and Asians/Pacific Islanders. Multivariable Cox regression analysis showed that African Americans had the highest hazard ratio for death.

ANNALS OF EPIDEMIOLOGY (2023)

Article Oncology

Taxifolin Inhibits Breast Cancer Growth by Facilitating CD8+T Cell Infiltration and Inducing a Novel Set of Genes including Potential Tumor Suppressor Genes in 1q21.3

Xiaozeng Lin, Ying Dong, Yan Gu, Anil Kapoor, Jingyi Peng, Yingying Su, Fengxiang Wei, Yanjun Wang, Chengzhi Yang, Armaan Gill, Sandra Vega Neira, Damu Tang

Summary: Breast cancer is the leading cause of cancer deaths in women and there is a need for improvement in risk estimation and effective therapies. In our research, we found that taxifolin inhibits breast cancer by increasing the expression of 36 genes. These genes effectively predict death probability in breast cancer patients, and aggressive breast cancers are associated with increases in the 1q21.3 DNA region. Taxifolin can induce the expression of tumor suppressor genes in this region, providing a novel mechanism for suppressing breast cancer. This study advances our understanding of breast cancer risk estimation and treatment.

CANCERS (2023)

Article Medicine, General & Internal

Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer

Amanjot Sidhu, Nabeeha Khan, Cameron Phillips, Juan Briones, Anil Kapoor, Pawel Zalewski, Neil E. Fleshner, Edward Chow, Urban Emmenegger

Summary: In this study, we found that approximately 20% of patients with metastatic castration-resistant prostate cancer (mCRPC) experience PSA flares induced by Ra223 treatment, and these flares are not closely associated with patient outcomes. Although only a few patients had PSA decreases greater than 30% after the flare, the overall survival was comparable to patients with PSA responses or non-responses.

JOURNAL OF CLINICAL MEDICINE (2023)

Meeting Abstract Oncology

Oxygen Enhanced-MRI for Hypoxia Imaging in Head and Neck Cancer

M. J. Dubec, J. Gaffney, A. Datta, D. L. Buckley, R. Little, A. Clough, C. Hague, M. Berks, S. Cheung, A. Salah, C. L. Eccles, R. G. Bristow, D. Higgins, J. H. Naish, J. Matthews, M. van Herk, G. J. Parker, A. Choudhury, J. P. O'Connor, A. McPartlin

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Article Oncology

Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer

Harry C. Brastianos, Jure Murgic, Adriana Salcedo, Melvin L. K. Chua, Alice Meng, Michael Fraser, Michael Brundage, Neil E. Fleshner, Theodorus van der Kwast, Robert G. Bristow, Paul C. Boutros, Alejandro Berlin

Summary: We investigated the impact of tumor heterogeneity on the accuracy of DNA-based biomarkers in predicting early relapse after prostatectomy. We found that the biomarkers maintained their predictive accuracy, suggesting that spatial heterogeneity may not hinder biomarker performance.

EUROPEAN UROLOGY ONCOLOGY (2022)

Meeting Abstract Urology & Nephrology

The effect of age on cancer-specifc mortality in T1a stage renal cell carcinoma patients: A population-based study across all treatment's modalities

A. Pecoraro, S. Knipper, C. Palumbo, G. Rosiello, S. Luzzago, M. Deuker, Z. Tian, S. F. Shariat, F. Saad, A. Briganti, A. Kapoor, S. De Cillis, A. Piana, F. Piramide, M. Sica, D. Amparore, E. Checcucci, M. Manfredi, C. Fiori, F. Porpiglia, P. Karakiewicz

EUROPEAN UROLOGY (2022)

Meeting Abstract Urology & Nephrology

Effect of 18F-DCFPyL PET/CT (=PSMA PET) on the management of patients with suspected limited residual/recurrent disease following radical prostatectomy: Results of a prospective, multicenter registry trial

J. Chin, U. Metser, K. Zukotynski, V Mak, D. Langer, P. Maccrostie, A. Finelli, A. Kapoor, L. Lavallee, L. Klotz, M. Hagerty, C. Hildebrand, G. Bauman

EUROPEAN UROLOGY (2022)

暂无数据